https://finance.yahoo.com/news/prometheus-biosciences-announces-positive-results-120000364.html
0
0
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb - Yahoo Finance
12/7/22 at 12:00pm
Organization
Yahoo Entertainment
Author
Prometheus Biosciences
Details
63 words
Summarize
Pharmaceuticals & Biotech Business & Industrial PRA023 Prometheus Biosciences Announces Positive Results Anti-TL1A mAb - Yahoo Finance -- ARTEMIS-UC Phase 2a Studies 26.5%
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p...
Create an account or login to join the discussion